Identification

Name
Bufexamac
Accession Number
DB13346
Type
Small Molecule
Groups
Approved, Experimental
Description

Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac. It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, and itching. It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids. The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [2]. Bufexamac was also withdrawn by the EMA in April 2010.

Structure
Thumb
Synonyms
  • 2-(p-Butoxyphenyl)-acetohydroxamic acid
  • 4-Butoxy-N-hydroxybenzeneacetamide
  • 4-Butoxyphenylacetohydroxamic acid
  • Acide p-butoxyphenylacethydroxamique
  • bufexamaco
  • bufexamacum
  • Bufexamic acid
  • p-Butoxyphenylacetohydroxamic acid
External IDs
CP 1044 J3 / CP-1044-J3
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norfemac Cream - 5%Cream5 %TopicalHoechst Marion Roussel1995-12-311999-08-11Canada
Norfemac Ointment - 5%Ointment5 %TopicalHoechst Marion Roussel1995-12-311999-08-11Canada
Categories
UNII
4T3C38J78L
CAS number
2438-72-4
Weight
Average: 223.272
Monoisotopic: 223.120843411
Chemical Formula
C12H17NO3
InChI Key
MXJWRABVEGLYDG-UHFFFAOYSA-N
InChI
InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
IUPAC Name
2-(4-butoxyphenyl)-N-hydroxyacetamide
SMILES
CCCCOC1=CC=C(CC(=O)NO)C=C1

Pharmacology

Indication

Indicated for the treatment of various skin conditions, such as atopic eczema and other inflammatory dermatoses.

Pharmacodynamics

Bufexamac is a topically-active anti-inflammatory agent that inhibits the cyclooxygenase enzyme. In cutaneous and deep experimental inflammation, topical administration of bufexamac exerted a dose-related anti-inflammatory effect [1]. In guinea pigs, bufexamax was shown to be more active than topical acetylsalicylic acid 5% or phenylbutazone 5% in delaying the local increase in temperature resulting from UV exposure [1]. Bufexamac is unlikely to have any effect on wound healing [1].

Mechanism of action

The full mechanism of action is unclear. It is proposed that bufexamac acts similarly to other non-steroidal anti-inflammatory drugs to inhibit prostaglandin biosynthesis in vitro, via inhibiting cyclo-oxygenase (COX) enzymes [1]. Systematically administered bufexamac may accumulate preferentially in the adrenal cortex of rats and may play a role in adrenal stimulation; however its topical anti-inflammatory action is likely to be independent of this effect [1].

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
UHistone deacetylase 6
inhibitor
Human
UHistone deacetylase 10
inhibitor
Human
Absorption

Method of application affects the extent of cutaneous absorption [1]. Following rectal administration as suppositories, the systemic absorption was reported to be low [3].

Volume of distribution

No data available.

Protein binding

No data available.

Metabolism

No data available.

Route of elimination

Following topical administration of 5% bufexamac, the recovery in the urine was 3.5% of the applied dose within 144 hours [1]. Studies in healthy volunteers receiving an oral dose of 125 to 500 mg indicate that an average of 80% of the total dose is excreted in the urine within 48 hours [1].

Half life

No data available.

Clearance

No data available.

Toxicity

The LD50 in rat following oral and intraperitoneal administration is 3370 mg/kg and 805 mg/kg, respectively [MSDS]. Subcutaneous LD50 in mouse is >5000 mg/kg [MSDS]. Mild skin irritation was seen in rabbits following dermal application of 750 mg/30d(l) [MSDS]. Non-steroidal anti-inflammatory drug (NSAID) overdose may produce nausea, vomiting, indigestion and upper abdominal pain. Other effects may include drowsiness, dizziness, confusion, disorientation, lethargy [MSDS].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bufexamac.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Bufexamac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Bufexamac is combined with 5-androstenedione.Experimental, Illicit
AbciximabBufexamac may increase the anticoagulant activities of Abciximab.Approved
AcebutololBufexamac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bufexamac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBufexamac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bufexamac.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Bufexamac.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bufexamac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Bufexamac is combined with Alendronic acid.Approved
AliskirenBufexamac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bufexamac.Experimental
AlprenololBufexamac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Bufexamac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideBufexamac may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Bufexamac is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bufexamac.Approved
AncrodBufexamac may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bufexamac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Bufexamac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Bufexamac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bufexamac.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Bufexamac.Approved, Investigational
Antithrombin III humanBufexamac may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Bufexamac is combined with Antrafenine.Approved
ApixabanBufexamac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Bufexamac.Investigational
ApramycinBufexamac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Bufexamac.Approved, Investigational
ArbekacinBufexamac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBufexamac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBufexamac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBufexamac may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineBufexamac may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Atamestane.Investigational
AtenololBufexamac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bufexamac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bufexamac.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Bufexamac is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bufexamac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bufexamac.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Bufexamac.Approved, Investigational
BazedoxifeneBufexamac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminBufexamac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Bufexamac.Approved, Investigational
BefunololBufexamac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBufexamac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Bufexamac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bufexamac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Bufexamac.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bufexamac.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bufexamac.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Bufexamac.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bufexamac.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bufexamac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Betamethasone.Approved, Vet Approved
BetaxololBufexamac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Bufexamac.Approved, Investigational
BevantololBufexamac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Bufexamac.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bufexamac.Approved, Investigational
BisoprololBufexamac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBufexamac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBufexamac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Bufexamac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bufexamac.Investigational
BucindololBufexamac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bufexamac.Approved
BufuralolBufexamac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Bufexamac.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bufexamac.Approved
BupranololBufexamac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bufexamac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bufexamac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bufexamac.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bufexamac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Bufexamac.Approved, Vet Approved, Withdrawn
CarteololBufexamac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBufexamac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bufexamac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Bufexamac.Approved, Investigational
CeliprololBufexamac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBufexamac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bufexamac.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bufexamac.Approved, Vet Approved
ChlorotrianiseneBufexamac may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bufexamac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bufexamac.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cimicoxib.Investigational
CinoxacinBufexamac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinBufexamac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Bufexamac.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Bufexamac.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Bufexamac.Vet Approved
CloranololBufexamac may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneBufexamac may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensBufexamac may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Bufexamac.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bufexamac.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Bufexamac is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateBufexamac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinBufexamac may increase the thrombogenic activities of Daidzein.Experimental
DalteparinBufexamac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBufexamac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Bufexamac.Investigational
DarexabanBufexamac may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Bufexamac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Bufexamac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Delapril.Investigational
DesipramineBufexamac may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinBufexamac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Bufexamac.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bufexamac.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Bufexamac is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bufexamac.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Bufexamac.Experimental
DextranBufexamac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinBufexamac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Bufexamac is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bufexamac.Approved, Vet Approved
DicoumarolBufexamac may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolBufexamac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolBufexamac may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Bufexamac.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bufexamac.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bufexamac.Approved
DihydrostreptomycinBufexamac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Bufexamac.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Bufexamac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bufexamac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Bufexamac.Approved
DiphenadioneBufexamac may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Bufexamac.Approved
DrospirenoneBufexamac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Bufexamac.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Bufexamac.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bufexamac.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Bufexamac.Investigational
Edetic AcidBufexamac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBufexamac may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Bufexamac.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bufexamac is combined with Enalaprilat.Approved
EnoxacinBufexamac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBufexamac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Bufexamac.Experimental
EpanololBufexamac may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolBufexamac may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Bufexamac.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bufexamac.Experimental
EplerenoneBufexamac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bufexamac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bufexamac.Approved
EquileninThe risk or severity of adverse effects can be increased when Bufexamac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Bufexamac is combined with Equilin.Approved
EquolBufexamac may increase the thrombogenic activities of Equol.Investigational
EsatenololBufexamac may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Bufexamac.Approved, Investigational
EsmololBufexamac may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateBufexamac may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateBufexamac may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateBufexamac may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolBufexamac may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedBufexamac may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bufexamac.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Bufexamac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Bufexamac.Experimental
Ethyl biscoumacetateBufexamac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Bufexamac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Bufexamac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bufexamac.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Bufexamac.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Bufexamac.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Bufexamac.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Bufexamac.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Bufexamac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bufexamac.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bufexamac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bufexamac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Bufexamac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bufexamac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Bufexamac.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Bufexamac.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bufexamac.Approved, Investigational
FleroxacinBufexamac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bufexamac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fludrocortisone.Approved, Investigational
FluindioneBufexamac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBufexamac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Bufexamac.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Bufexamac.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Bufexamac.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Bufexamac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bufexamac.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Bufexamac.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Bufexamac.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bufexamac.Approved, Nutraceutical, Vet Approved
FondaparinuxBufexamac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Bufexamac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bufexamac is combined with Fosinopril.Approved
FramycetinBufexamac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bufexamac.Approved, Vet Approved
GabexateBufexamac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBufexamac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBufexamac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Bufexamac.Approved, Withdrawn
GemifloxacinBufexamac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBufexamac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinBufexamac may increase the thrombogenic activities of Genistein.Investigational
GentamicinBufexamac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABufexamac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Bufexamac.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Bufexamac.Approved
GrepafloxacinBufexamac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Bufexamac.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Bufexamac.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Bufexamac is combined with HE3286.Investigational
HeparinBufexamac may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolBufexamac may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Bufexamac.Investigational
HydralazineBufexamac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bufexamac.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bufexamac.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Bufexamac.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Bufexamac.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bufexamac.Approved, Investigational
Hygromycin BBufexamac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Bufexamac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bufexamac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Bufexamac.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Bufexamac.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Bufexamac is combined with Icosapent.Approved, Nutraceutical
IdraparinuxBufexamac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bufexamac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Bufexamac.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Bufexamac.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bufexamac.Approved
IndenololBufexamac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Bufexamac.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bufexamac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bufexamac.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bufexamac.Approved, Investigational
IsepamicinBufexamac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bufexamac.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Bufexamac.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Bufexamac is combined with Istaroxime.Investigational
KanamycinBufexamac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bufexamac.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Bufexamac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bufexamac.Approved
LabetalolBufexamac may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bufexamac.Approved, Investigational
LandiololBufexamac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bufexamac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Bufexamac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Bufexamac.Approved, Investigational
LepirudinBufexamac may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bufexamac.Approved, Investigational
LetaxabanBufexamac may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololBufexamac may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololBufexamac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBufexamac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Bufexamac.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Bufexamac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bufexamac.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Bufexamac.Experimental
LomefloxacinBufexamac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Bufexamac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Bufexamac.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bufexamac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bufexamac.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bufexamac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Bufexamac.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Bufexamac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bufexamac.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Bufexamac.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bufexamac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Bufexamac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bufexamac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bufexamac.Approved
MelagatranBufexamac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bufexamac.Approved, Vet Approved
MepindololBufexamac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Bufexamac.Approved
MestranolBufexamac may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bufexamac.Approved, Investigational, Withdrawn
MethallenestrilBufexamac may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bufexamac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bufexamac.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Bufexamac.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Bufexamac.Approved, Vet Approved
MetipranololBufexamac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bufexamac.Approved
MetoprololBufexamac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Bufexamac.Investigational, Withdrawn
MicronomicinBufexamac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Bufexamac.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Bufexamac.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Bufexamac.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bufexamac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bufexamac.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Bufexamac.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bufexamac.Approved
MoxestrolBufexamac may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinBufexamac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bufexamac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bufexamac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Bufexamac.Approved
NadololBufexamac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBufexamac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bufexamac.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bufexamac.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bufexamac.Investigational
Nalidixic AcidBufexamac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Bufexamac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Bufexamac is combined with NCX 1022.Investigational
NeamineBufexamac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBufexamac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Bufexamac.Approved, Withdrawn
NemonoxacinBufexamac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Bufexamac.Approved, Investigational
NetilmicinBufexamac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Bufexamac.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Bufexamac.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Bufexamac.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Bufexamac.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Bufexamac.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bufexamac.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Bufexamac.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bufexamac.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bufexamac.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bufexamac.Investigational
NorfloxacinBufexamac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBufexamac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bufexamac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bufexamac.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bufexamac.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Bufexamac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Bufexamac is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Bufexamac.Vet Approved
OtamixabanBufexamac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Bufexamac.Approved
Oxolinic acidBufexamac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBufexamac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bufexamac.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Bufexamac.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Bufexamac.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Bufexamac.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Bufexamac.Approved, Investigational
PazufloxacinBufexamac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBufexamac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBufexamac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBufexamac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBufexamac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Perindopril.Approved
PhenindioneBufexamac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBufexamac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bufexamac.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bufexamac.Approved, Investigational
PindololBufexamac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidBufexamac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bufexamac.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bufexamac.Approved, Investigational
Piromidic acidBufexamac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bufexamac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Bufexamac.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBufexamac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBufexamac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateBufexamac may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bufexamac.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pomalidomide.Approved
Potassium CitrateBufexamac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololBufexamac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Bufexamac.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Bufexamac.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Bufexamac.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Bufexamac can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Bufexamac.Experimental
PromestrieneBufexamac may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bufexamac.Approved, Investigational
PropafenoneBufexamac may decrease the antihypertensive activities of Propafenone.Approved
PropranololBufexamac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Bufexamac.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Bufexamac.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Bufexamac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Bufexamac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Bufexamac.Vet Approved
Protein CBufexamac may increase the anticoagulant activities of Protein C.Approved
Protein S humanBufexamac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBufexamac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBufexamac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Bufexamac.Investigational
PuromycinBufexamac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Quinapril.Approved, Investigational
QuinestrolBufexamac may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bufexamac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Bufexamac is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bufexamac.Approved, Experimental, Investigational
ReviparinBufexamac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBufexamac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Risedronate.Approved, Investigational
RivaroxabanBufexamac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Bufexamac.Approved, Investigational, Withdrawn
RosoxacinBufexamac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBufexamac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bufexamac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bufexamac.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bufexamac.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Bufexamac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bufexamac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Bufexamac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Bufexamac.Approved, Investigational
SecoisolariciresinolBufexamac may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Bufexamac is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Bufexamac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bufexamac.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bufexamac.Investigational
SertralineSertraline may increase the antiplatelet activities of Bufexamac.Approved
SisomicinBufexamac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBufexamac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Bufexamac is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Bufexamac.Approved
SotalolBufexamac may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinBufexamac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bufexamac is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Bufexamac.Investigational
StreptomycinBufexamac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bufexamac.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bufexamac.Approved, Investigational
SulodexideBufexamac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Bufexamac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Bufexamac.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Bufexamac.Experimental
Synthetic Conjugated Estrogens, ABufexamac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BBufexamac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusBufexamac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Bufexamac.Approved
TalinololBufexamac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Bufexamac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bufexamac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bufexamac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bufexamac.Approved, Investigational
TemafloxacinBufexamac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Bufexamac.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bufexamac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Bufexamac.Vet Approved
TerbutalineBufexamac may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bufexamac.Approved
TertatololBufexamac may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Bufexamac.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Bufexamac.Approved
TiboloneBufexamac may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Bufexamac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBufexamac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bufexamac.Investigational
TioclomarolBufexamac may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Tixocortol.Approved, Withdrawn
TobramycinBufexamac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Bufexamac.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bufexamac.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bufexamac.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bufexamac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bufexamac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Bufexamac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBufexamac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bufexamac.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bufexamac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Bufexamac.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Bufexamac is combined with Trolamine salicylate.Approved
TrovafloxacinBufexamac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBufexamac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bufexamac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Bufexamac.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bufexamac.Approved, Investigational
VancomycinBufexamac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Bufexamac.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Bufexamac.Approved
WarfarinBufexamac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBufexamac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bufexamac.Approved, Investigational
ZeranolBufexamac may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Bufexamac.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Bufexamac.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Bufexamac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Bufexamac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bufexamac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10(5-6):351-6. [PubMed:1204506]
  2. Kranke B, Szolar-Platzer C, Komericki P, Derhaschnig J, Aberer W: Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Contact Dermatitis. 1997 Apr;36(4):212-5. [PubMed:9165205]
  3. Glowania HJ, Hampl B: [Results of a study of the resorption of bufexamac following rectal administration]. Z Hautkr. 1988 Mar 21;63(3):211. [PubMed:3388925]
External Links
KEGG Drug
D01271
PubChem Compound
2466
PubChem Substance
347829293
ChemSpider
2372
BindingDB
50015144
ChEBI
31317
ChEMBL
CHEMBL94394
HET
A4Z
Wikipedia
Bufexamac
ATC Codes
M02AA09 — BufexamacM01AB17 — Bufexamac
PDB Entries
5bpp
MSDS
Download (352 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical5 %
OintmentTopical5 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)153 to 155MSDS
water solubilityImmiscibleMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.233 mg/mLALOGPS
logP2.09ALOGPS
logP1.97ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.86ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity61.29 m3·mol-1ChemAxon
Polarizability24.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-1090000000-f24ae0d85b1376dd6695
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-5390000000-1064111002b4036cfbbb
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aor-7900000000-789660a43653a49880b8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-066r-5900000000-91ae318ee7bf4a0c8ebb
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-4900000000-15c66804db050221c331
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-3900000000-a41498b64629a3eda39c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0920000000-9e2d982e08339f818cf6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bt9-0900000000-435c1f72113403e534fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0900000000-9de68224c670d85b5621
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0900000000-496edd1f1dfb18e3bc93
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-1900000000-3e269c82012ba53557c2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-2900000000-80c7b8b429b26dfbbfc6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-08mi-0920000000-e2854ce6292c5d0a1c8c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-4910100000-7ff98d442e9aa0a2f64d

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Hydroxamic acids / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenylacetamide / Phenoxy compound / Phenol ether / Alkyl aryl ether / Hydroxamic acid / Carboxylic acid derivative / Ether / Organopnictogen compound / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, hydroxamic acid (CHEBI:31317)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10(5-6):351-6. [PubMed:1204506]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. Drugs. 1975;10(5-6):351-6. [PubMed:1204506]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC6
Uniprot ID
Q9UBN7
Uniprot Name
Histone deacetylase 6
Molecular Weight
131418.19 Da
References
  1. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G: Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29(3):255-65. doi: 10.1038/nbt.1759. Epub 2011 Jan 23. [PubMed:21258344]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.
Specific Function
Enzyme binding
Gene Name
HDAC10
Uniprot ID
Q969S8
Uniprot Name
Histone deacetylase 10
Molecular Weight
71444.08 Da
References
  1. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G: Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29(3):255-65. doi: 10.1038/nbt.1759. Epub 2011 Jan 23. [PubMed:21258344]

Drug created on June 23, 2017 14:40 / Updated on August 02, 2018 06:51